UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 123

Sortiert nach

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

BMC cancer, 2009-01, Vol.9 (1), p.8-8, Article 8

2009

Link zum Volltext

Verfügbarkeit prüfen

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

Acta obstetricia et gynecologica Scandinavica, 2012-04, Vol.91 (4), p.496-502

2012

Link zum Volltext

Verfügbarkeit prüfen

Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2023-10, Vol.131 (10), p.536-542

2023

Link zum Volltext

Verfügbarkeit prüfen

CT versus FDG‐PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Cancer medicine (Malden, MA), 2014-10, Vol.3 (5), p.1294-1301

2014

Link zum Volltext

Verfügbarkeit prüfen

Association of CD31 and p53 With Survival of Ovarian Cancer Patients

Anticancer research, 2019-02, Vol.39 (2), p.567-576

2019

Link zum Volltext

Verfügbarkeit prüfen

Association of Reproductive Factors, Oral Contraceptive Use and Selected Lifestyle Factors with the Risk of Ovarian Borderline Tumors: A Danish Case-Control Study

Cancer causes & control, 2006-08, Vol.17 (6), p.821-829

2006

Link zum Volltext

Verfügbarkeit prüfen

YKL-40 protein expression in normal adult human tissues--an immunohistochemical study

Journal of Molecular Histology, 2007-03, Vol.38 (1), p.33-43

2007

Link zum Volltext

Verfügbarkeit prüfen

Annexin A2 and cancer: A systematic review

International journal of oncology, 2018-01, Vol.52 (1), p.5-18

2018

Link zum Volltext

Verfügbarkeit prüfen

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA Ovarian Cancer Study

Cancer, 2003-07, Vol.98 (1), p.66-73

2003

Link zum Volltext

Verfügbarkeit prüfen

HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review

Cancer epidemiology, biomarkers & prevention, 2014-11, Vol.23 (11), p.2285-2295

2014

Link zum Volltext

Verfügbarkeit prüfen

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

Scandinavian journal of clinical and laboratory investigation, 2014-09, Vol.74 (6), p.477-484

2014

Link zum Volltext

Verfügbarkeit prüfen

Serum YKL-40 and gestational diabetes - an observational cohort study

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2016-09, Vol.124 (9), p.770-775

2016

Link zum Volltext

Verfügbarkeit prüfen

Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2013-01, Vol.121 (1), p.38-44

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2006-10, Vol.114 (10), p.675-681

2006

Link zum Volltext

Verfügbarkeit prüfen

Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2008-05, Vol.116 (5), p.400-409

2008

Link zum Volltext

Verfügbarkeit prüfen

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

Acta obstetricia et gynecologica Scandinavica, 2003-03, Vol.82 (3), p.287-293

2003

Link zum Volltext

Verfügbarkeit prüfen

Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2010-08, Vol.118 (8), p.557-564

2010

Link zum Volltext

Verfügbarkeit prüfen

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study

Gynecologic oncology, 2007-03, Vol.104 (3), p.508-515

2007

Link zum Volltext

Verfügbarkeit prüfen

Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: From the danish MALOVA ovarian carcinoma study

Cancer, 2004-06, Vol.100 (11), p.2387-2395

2004

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients : From the 'MALOVA' Ovarian Cancer Study

Oncology reports, 2007-11, Vol.18 (5), p.1051-1059

2007

Link zum Volltext

Verfügbarkeit prüfen

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Gynecologic oncology, 2011-11, Vol.123 (2), p.308-313

2011

Link zum Volltext

Verfügbarkeit prüfen

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4051-4058

2004

Link zum Volltext

Verfügbarkeit prüfen

Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2015-05, Vol.123 (5), p.401-409

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(115)

Publikationsform

Artikel
(123)

Sprache

Englisch
(122)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass

Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?

CT versus FDG‐PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Association of CD31 and p53 With Survival of Ovarian Cancer Patients

Association of Reproductive Factors, Oral Contraceptive Use and Selected Lifestyle Factors with the Risk of Ovarian Borderline Tumors: A Danish Case-Control Study

YKL-40 protein expression in normal adult human tissues--an immunohistochemical study

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab

Annexin A2 and cancer: A systematic review

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA Ovarian Cancer Study

HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

Serum YKL-40 and gestational diabetes - an observational cohort study

Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study

Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: From the danish MALOVA ovarian carcinoma study

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients : From the 'MALOVA' Ovarian Cancer Study

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass

Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study

Suchergebnisse filtern